Daily Insider Ratings Report: Dec 7, 2017
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research processInfinity Pharmaceuticals is a biopharmaceutical company focused on developing medicines for people with cancer. The company is focusing its efforts on developing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma. The company's ongoing Phase 1/1b study MAcrophage Reprogramming in Immuno-Oncology is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for IPI-549 both as a monotherapy and in combination with nivolumab, also known as Opdivo?, in patients with advanced solid tumors.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.